The detection and diagnosis of Niemann-Pick disease type C

Activity information

Release Date: August 29, 2026 · Expiration Date: August 29, 2027

Activity Overview
This case-based educational program is designed to improve clinician competence in the early recognition and diagnosis of Niemann–Pick disease type C (NPC). Through two interactive virtual patient simulations based on real-world diagnostic scenarios, participants will learn to identify age-dependent clinical red flags, differentiate NPC from common neurologic and psychiatric mimics, apply contemporary diagnostic pathways, interpret biomarker and genetic testing results, and recognize the diagnostic significance of ocular motor abnormalities such as vertical supranuclear saccade palsy. The activity aims to reduce diagnostic delay and support earlier referral and multidisciplinary evaluation of children and adolescents with suspected NPC.

Target Audience
This activity is designed for an audience of Physicians.

Learning Objectives
Upon completion of the educational activity, participants should be able to:

• Recognize age-dependent NPC red flags in early childhood, including unexplained splenomegaly, developmental concerns, progressive gait or coordination changes, and cataplexy-like events

• Differentiate NPC from common pediatric mimics

• Apply current diagnostic pathways for suspected pediatric NPC, including appropriate selection and sequencing of biomarker testing and confirmatory genetic evaluation to reduce time to diagnosis

• Evaluate and interpret challenging diagnostic results in pediatric NPC

• Implement practice changes to enable earlier identification and referral, including when to escalate testing, coordinate multidisciplinary evaluation, and initiate longitudinal monitoring to improve outcomes

• Recognize the diagnostic significance of ocular motor abnormalities and understand when their presence should prompt NPC evaluation

Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at ketrea@akhcme.com.

https://akhcme.com/content/detection-and-diagnosis-niemann-pick-type-c

Credit Claim Instructions

1. Click the claim link

2. Login or Create an account in the system. (All 1st time users required to create an account)

Once complete, the course will appear in your 'Pending Activities' list, found under the 'Activities' tab on your profile page (upper right-hand corner).

3. Proceed to Register/Take Course Tab to complete the Course Evaluation & Certificate steps for the activity.

4. Click get started

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Orakle LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
This activity is supported from an independent medical education grant from Zevra Therapeutics.

Disclosures

NameRelationshipCommercial Interest
Barbara Burton MD (faculty)SpeakerBiomarin, Zevra
Barbara Burton MD (faculty)ConsultantAlltrna, Applied Therapeutics, Chiesi, Denali, JCR Pharma, Moderna, Ultragenyx, Uniqure
Caroline Hastings MD (faculty)ConsultantAzafaros, Zevra, IntraBio, Cyclo Therapeutics
Dorothy Caputo, MA, BSN, RN - PresidentN/ANothing to disclose
Rebecca Lakowski, RN (planner/reviewer)N/ANothing to disclose
AKH Inc Staff and PlannersN/ANothing to disclose
Orakle LLC Staff and PlannersN/ANothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.

Pre-test

Answered before any case content is shown · answers are recorded, feedback follows the post-test.

A short professional profile and one question. Your answers power the outcome analysis for this activity; they are never used to judge you individually.

Pre-test · Question 1 of 1

According to the 2025 Consensus Clinical Management Guidelines for Niemann–Pick disease type C, which of the following represents the most appropriate diagnostic approach when NPC is clinically suspected in a child or adolescent with progressive neurological symptoms?

Select an answer to continue

Introduction

History of Present Illness

Welcome. Your patient today is Daniel, a 15-year-old boy referred for evaluation of progressive cognitive and behavioral decline associated with episodic staring spells and abnormal eye movements.

Over the past 18 months, Daniel has experienced worsening concentration, declining academic performance, emotional withdrawal, and episodes of inappropriate laughter and irritability. His parents describe intermittent “blank spells” during which he suddenly stops speaking and stares for several seconds before recovering immediately. Initial psychiatric assessment suggested attention-deficit/hyperactivity disorder (ADHD), and stimulant therapy was initiated; however, despite dose escalation, his symptoms continued to progress without meaningful improvement. An electroencephalogram (EEG) demonstrated mild nonspecific generalized slowing without definite epileptiform discharges. Although this finding did not confirm epilepsy, it also did not exclude seizure activity, particularly given Daniel’s ongoing episodic staring spells and progressive neurological symptoms.

More recently, Daniel has developed subtle dysarthria, intermittent dystonic posturing of the hands, and increasing difficulty tracking objects visually, particularly when looking upward. Ophthalmologic assessment documented impaired vertical saccades, with Daniel compensating by moving his head rather than his eyes. Given the progressive neurological features, poor response to ADHD treatment, and abnormal ocular findings, Daniel has now been referred to you for further evaluation.

Physical examination is notable for mildly slowed speech with occasional subtle dysarthria. Mild intermittent dystonic posturing of the hands is observed during fine motor tasks. Daniel is alert and oriented, and his strength, muscle tone, coordination, sensation, reflexes, and gait are otherwise normal.

Given the progressive neurological features, poor response to ADHD treatment, and abnormal ocular findings, you begin to question whether ADHD adequately explains Daniel’s presentation. Before proceeding with laboratory investigations, you decide to obtain a more detailed developmental and family history from Daniel’s mother.

Consultation

Ask the patient — choose a question to play the interview.

Full transcripts below

Transcript · Ask about Daniel’s family history

Physician: Has anyone else in the family had neurological or psychiatric problems?

Mother: No, none that we’re aware of.

Mother: Not really. My father developed dementia in his seventies.

Physician: Anyone with symptoms like Daniel’s at a young age?

Mother: No, nothing like this.

Physician: Any relatives with seizures, movement problems, or learning difficulties?

Transcript · Explore Daniel’s ADHD diagnosis

Physician: How did Daniel respond to the ADHD medication?

Mother: Honestly, we didn’t notice much improvement at all.

Physician: Did his concentration improve at school?

Mother: No, his grades kept getting worse despite increasing the dose.

Physician: Any side effects from the medication?

Mother: He became quieter and more withdrawn, but the staring spells continued.

Physician: Did the medication help the unusual eye movement symptoms?

Mother: No, if anything, those became more noticeable over time.

Physician: ADHD alone would not usually explain progressive speech changes or abnormal eye movements.

Mother: That’s what’s been worrying us. It feels like something else is going on.

Physician: The lack of response to stimulant therapy and the progression of symptoms suggest we should investigate for an underlying neurological condition.

Tests

Select appropriate tests for the patient — order and sequence are part of the exercise.

Brain magnetic resonance imaging (MRI)

Detailed oculomotor assessment

Whole exome/genome sequencing

Diagnoses

Select the best diagnosis.

Your first answer is recorded before any feedback is shown — commit to the classification you would act on.

NameAction
Select a diagnosis to continue

Post-test

The same two questions you answered before the case — now with full feedback. A score of 70% or better is required for the certificate.

Post-test · Question 1 of 1

According to the 2025 Consensus Clinical Management Guidelines for Niemann–Pick disease type C, which of the following represents the most appropriate diagnostic approach when NPC is clinically suspected in a child or adolescent with progressive neurological symptoms?

Select an answer to continue

Your details

Needed to issue your certificate and send your enduring materials.

Please confirm how we should address you and where to send your certificate and downloadable resources. These details go only to Orakle and AKH for accreditation and delivery — never to the activity's supporter.

All three fields are required — email must be valid

Case Review

Daniel’s case highlights how NPC can initially mimic more common adolescent neurological and psychiatric disorders, including ADHD and epilepsy. His early symptoms—declining concentration, behavioral change, staring spells, and academic deterioration—made the initial ADHD diagnosis understandable, particularly in the absence of obvious systemic findings such as hepatosplenomegaly or cerebellar ataxia (both of which were absent in this case). Similarly, the intermittent staring episodes and nonspecific EEG slowing created a reasonable concern for seizure-related pathology.

However, the key clinical lesson is that progressive neurological symptoms and the emergence of objective neurological findings should prompt reconsideration of the original diagnosis. Although not all patients with ADHD respond adequately to stimulant therapy, Daniel continued to demonstrate progressive cognitive and behavioral decline despite treatment. The subsequent development of dysarthria, dystonic posturing, and especially VSGP represented important neurological “red flag” findings that are not explained by uncomplicated ADHD and warranted further investigation for an underlying neurodegenerative disorder.

Careful reassessment of the diagnosis, combined with targeted neurological examination and metabolic investigation, ultimately revealed elevated pathogenic NPC1 variants, confirming juvenile-onset NPC. This case emphasizes the importance of revisiting initial assumptions when the clinical course becomes atypical, progressive, or treatment-resistant, particularly in adolescents with evolving neuropsychiatric symptoms.

Evaluation

How satisfied were you with this case?

1 · Not at all satisfied10 · Extremely satisfied

How useful did you find this activity in enhancing your knowledge and skills for improving patient care in your clinical practice?

To what extent were the stated learning objectives met as a result of this activity?

Overall, how would you rate the quality and content presented by the experts in this activity?

How confident are you in applying the information from this activity to patient care?

Following this activity, do you plan to seek additional information on this topic?

Please indicate your level of agreement with the following statements about this activity:

SA = Strongly agree · A = Agree · N = Neutral · D = Disagree · SD = Strongly disagree

The content presented was relevant to my clinical practice.
The activity provided practical information that I can apply in my clinical practice.
This activity was free of commercial bias.
The content provided a fair and balanced coverage of the topic.
The learning activities were effective and incorporated active learning methods.
The educational materials were effective.
My educational needs were met by this activity.

Based on the information presented in the activity, I will:

Will this case change how you manage these patients?

May we contact you in 45 days for a brief follow-up survey on how this activity affected your practice?

Answer every evaluation item above to finish

The detection and diagnosis of Niemann-Pick disease type C

Learning Objectives — Upon completion of the educational activity, participants should be able to:

• Recognize age-dependent NPC red flags in early childhood, including unexplained splenomegaly, developmental concerns, progressive gait or coordination changes, and cataplexy-like events

• Differentiate NPC from common pediatric mimics

• Apply current diagnostic pathways for suspected pediatric NPC, including appropriate selection and sequencing of biomarker testing and confirmatory genetic evaluation to reduce time to diagnosis

• Evaluate and interpret challenging diagnostic results in pediatric NPC

• Implement practice changes to enable earlier identification and referral, including when to escalate testing, coordinate multidisciplinary evaluation, and initiate longitudinal monitoring to improve outcomes

• Recognize the diagnostic significance of ocular motor abnormalities and understand when their presence should prompt NPC evaluation

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Orakle LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians — AKH Inc., Advancing Knowledge in Healthcare designates this enduring for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support — This activity is supported from an independent medical education grant from Zevra Therapeutics.

WelcomePre-testIntroductionConsultationTestsDiagnosesPost-testDetailsSummary